ArticleTherapeutic advances in urology
Prognostic value of the inflammatory burden index for disease-specific mortality and intensive care need in Fournier's gangrene.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fournier's gangrene (FG) is a rapidly progressive necrotizing infection with high mortality. Early recognition of high-risk patients is critical for improving outcomes. Objectives: To evaluate the prognostic value of the Inflammatory Burden Index (IBI)-a composite marker derived from C-reactive protein, neutrophil, and lymphocyte counts-for predicting mortality, intensive care requirements, and clinical course in FG. Design and methods: This retrospective cohort included 130 patients diagnosed with FG and treated at a tertiary referral center between 2015 and 2025. Demographic, clinical, and laboratory data were collected at admission. IBI was calculated using first-draw laboratory values. Primary outcomes were disease-specific mortality and intensive care unit (ICU) admission; secondary outcome was length of hospital stay. Univariable and multivariable logistic regression analyses were performed, and discriminatory capacity was evaluated using receiver operating characteristic analysis. Results: Nonsurvivors exhibited significantly higher IBI values than survivors ( Conclusion: Admission IBI is an independent predictor of mortality, ICU requirement, and hospital stay in FG. As a simple, cost-effective, and rapidly available biomarker, IBI may support early risk stratification and decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.